$1.030
-0.713 (-69.25%)收盘时
- 最高
- 3.420
- 开盘
- 3.340
- 成交量加权均价
- 1.76
- 成交量
- 1.22M
- 市值
- —
- 最低
- 0.840
- 成交额
- 2.16M
- 企业价值/息税折旧摊销前利润(TTM)
- 0.00
ENvue Medical, Inc. is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Its segments include NanoVibronix, ENvue and Corporate. NanoVibronix is engaged in selling its products directly to patients as well as through distributor agreements. ENvue is engaged in selling its systems and Nasoenteral tubes and related services. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract.
AI 分析 of ENvue Medical Inc (FEED)
卖出ENvue Medical, Inc. (FEED) is not a good buy right now due to its extremely low price of $1.03, a staggering year-to-date change of -96.50%, and an RSI of 7.252 indicating oversold conditions. The company has also reported a gross margin of -111.30% in Q2 2026, highlighting severe profitability issues. The main risk is its recent performance, with a 5-day change of -75.93%, indicating continued downward pressure on the stock.
估值指标
事件时间线
资讯
7.509-09NewsfilterENvue Resumes Commercial Shipments of PainShield
8.509-02NewsfilterENvue Medical to Showcase Navigation Platform at Vizient Innovative Technology Exchange
8.508-28NASDAQ.COMENvue Medical Announces 1-for-12 Reverse Stock Split
8.508-28NewsfilterENvue Medical Announces Reverse Stock Split Effective September 1, 2026
8.508-12NewsfilterENvue Medical Secures $50 Million Equity Facility
FEED 常见问题 —— 由 Alphio AI 解答
ENvue Medical, Inc. is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Its segments include NanoVibronix, ENvue and Corporate. NanoVibronix is engaged in selling its products directly to patients as well as through distributor agreements. ENvue is engaged in selling its systems and Nasoenteral tubes and related services. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. It operates in the Healthcare sector.
ENvue Medical, Inc. (FEED) is not a good buy right now due to its extremely low price of $1.03, a staggering year-to-date change of -96.50%, and an RSI of 7.252 indicating oversold conditions. The company has also reported a gross margin of -111.30% in Q2 2026, highlighting severe profitability issues. The main risk is its recent performance, with a 5-day change of -75.93%, indicating continued downward pressure on the stock.
社区
更多 ↗暂无帖子
注册或登录后参与讨论相关文章
- Money Market Funds vs High-Yield Savings vs T-Bills: Where to Park Cash as the Fed HikesMoney market funds, high-yield savings or T-bills? Compare November 2026 yields, taxes, FDIC rules and liquidity as the Fed hikes, and build a smart cash plan.
- Homebuilder Stocks With Mortgage Rates Above 7%: An Investor's Guide for Late 2026Homebuilder stocks face 7% mortgage rates and a 16-year low in home sales. See what D.R. Horton, Lennar and Pulte earnings show and how to invest in 2026.
- Bitcoin Bear Market 2026: Why BTC Fell Below $70K and How Investors Can Manage Crypto RiskBitcoin is about 45% below its $126K peak as Fed hikes, 5% yields and ETF outflows bite. See how the 2026 bear market compares and how to manage crypto risk.
本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。